Abstract
3/2019
vol. 5
Review paper
Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
- Department of Infectious Diseases and Hepatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
- Department of Infectious Diseases and Hepatology, Medical University of Białystok, Poland
- Department of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poland
- Provincial Hospital of Infectious Diseases and Medical University in Warsaw, Poland
- Department of Haematology, Institute of Haematology and Transfusion Medicine in Warsaw, Poland
- Department of Clinical Transplantology, Medical University of Lublin, Poland
- Department and Clinical Unit of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland
- Department of Paediatrics, Haematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
Clin Exp HEPATOL 2019; 5, 3:195–202
Online publish date: 2019/09/05
Hepatitis B virus (HBV) is one of the main causes of chronic liver diseases and hepatocellular carcinoma. After infection the majority of HBV-infected patients achieve immune control leading to HBV-DNA stabilization at a low level. The risk of HBV reactivation rises significantly when HBV-infected patients receive immunosuppressive treatments. Presented recommendations provide guidelines for management of patients scheduled or undergoing therapies, which through their immunomodulatory activity contribute to the impairment of antiviral immunity, including chemotherapy, immunosuppressive treatment or biological therapy.
Keywords
HBV, prevention, reactivation
Coverage in
Integrated with
